The purpose of this study was to provide information on the prevalence of the use of prescription drugs among pregnant women in the United States.
A retrospective study was conducted with the use of the automated databases of 8 health maintenance organizations that are involved in the Health Maintenance Research Network Center for Education and Research on Therapeutics. Women who delivered of an infant in a hospital from January 1, 1996, through December 31, 2000, were identified. Prescription drug use according to therapeutic class and the United States Food and Drug Administration risk classification system was evaluated, with the assumption of a gestational duration of 270 days, with three 90-day trimesters of pregnancy, and with a 90-day period before pregnancy. Nonprescription drug use was not assessed.
During the period 1996 through 2000, 152,531 deliveries were identified that met the criteria for study. For 98,182 deliveries (64%), a drug other than a vitamin or mineral supplement was prescribed in the 270 days before delivery: 3595 women (2.4%) received a drug from category A; 76,292 women (50.0%) received a drug from category B; 57,604 women (37.8%) received a drug from category C; 7333 women (4.8%) received a drug from category D, and 6976 women (4.6%) received a drug from category X of the United States Food and Drug Administration risk classification system. Overall, 5157 women (3.4%) received a category D drug, and 1653 women (1.1%) received a category X drug after the initial prenatal care visit.
Our finding that almost one half of all pregnant women received prescription drugs from categories C, D, or X of the United States Food and Drug Administration risk classification system highlights the importance of the need to understand the effects of these medications on the developing fetus and on the pregnant woman.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to American Journal of Obstetrics & Gynecology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Good and bad prescription in pregnancy.Lancet. 2000; 356: 1704
- Drug use in first pregnancy and lactation: a population-based survey among Danish women.Eur J Clin Pharmacol. 1999; 55: 139-144
- Use of prescription and non-prescription drugs in pregnancy.J Clin Epidemiol. 1993; 46: 581-589
- Drug prescribing during pregnancy: a controlled study of Tennessee Medicaid recipients.Am J Obstet Gynecol. 1978; 132: 235-244
- Prescription drug use before and during pregnancy in a Medicaid population.Am J Obstet Gynecol. 1987; 157: 148-156
- Medication in early pregnancy: prevalence of use and relationship to maternal characteristics.Am J Obstet Gynecol. 1991; 165: 33-40
- Maternal use of prescribed drugs associated with recognized fetal adverse drug reactions.Am J Obstet Gynecol. 1988; 159: 1173-1177
- Drug use in pregnancy: an overview of epidemiological (drug utilization) studies.Eur J Clin Pharmacol. 1990; 38: 325-328
- Medication during pregnancy: an intercontinental cooperative study.Int J Gynecol Obstet. 1992; 39: 185-196
- Drug use in pregnancy among Italian women.Eur J Clin Pharmacol. 2000; 56: 323-328
- Prescription of drugs during pregnancy in France.Lancet. 2000; 356: 1735-1736
- Prescribing during pregnanacy and lactation with reference to the Swedish classification system: a population-based study among Danish women.Acta Obstet Gynecol Scand. 1999; 78: 686-692
- Classification of medicinal products for use during pregnancy and lactation: the Swedish systems. LINFO, Drug Information Ltd, Kungsbacka, Sweden1993
- A reference guide to fetal and neonatal risk- drugs in pregnancy and lactation.5th ed. Lippincott Williams & Wilkins, Philadephia1998
- Prenatal use of medications by women giving birth at a university hospital.South Med J. 1997; 90: 498-502
- Review of pregnancy labeling of prescription drugs: Is the current system adequate to inform of risks?.Am J Obstet Gynecol. 2002; 187: 333-339
- Shojania K. Duncan B. McDonald K. Wachter R.M. Making health care safer: a critical analysis of patient safety practices. Evidence report/technology assessment no. 43; AJRQ publication 01-E058. Agency for Healthcare Research and Quality, Rockville (MD)2001
Accepted: April 21, 2004
Received in revised form: April 1, 2004
Received: October 29, 2003
☆Supported by grant HS10391 from the Agency for Healthcare Research and Quality to The HMO Research Network Center for Education and Research in Therapeutics (CERT).
© 2004 Elsevier Inc. Published by Elsevier Inc. All rights reserved.